3 Beaten-Down Biotech Stocks to Buy Right Now
Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities. Not all beaten-down biotech stocks, though, are diamonds in the rough.
Among the 15 biotech companies that saw their shares slide by more than 10% last month, for instance, I'd personally only consider buying shares of three: Intercept Pharmaceuticals (NASDAQ: ICPT), Exelixis (NASDAQ: EXEL), and Sage Therapeutics (NASDAQ: SAGE). Here's why.
Image Source: Getty Images.
Source: Fool.com
Exelixis Inc. Aktie
44,31 €
0,46 %
Positive Stimmung für Exelixis Inc. mit mehreren Buy- gegenüber Sell-Einschätzungen.
Ein negatives Potenzial von -2.96% für Exelixis Inc., selbst mit einem niedrigeren Kursziel von 43 € als 44.31 €.
